Gene Therapy 2 to Target Mesothelin for Oncology is under clinical development by Tmunity Therapeutics and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase I drugs for Pancreatic Cancer have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Gene Therapy 2 to Target Mesothelin for Oncology’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Gene Therapy 2 to Target Mesothelin for Oncology overview

Gene therapy is under investigation for the treatment of malignant pleural mesothelioma, advanced leukemia, lung cancer, ovarian cancer and pancreatic cancer. It is administered intravenously. The therapy comprises of autologous chimeric immune receptor (CIR) T cells transfected with anti-mesothelin messenger RNA (mRNA) expressing a single chain antibody fragment linked to CD 3 zeta T cell receptor and 4-1BB costimulatory domains (CARTmeso cells). The therapy targets mesothelin-expressing cancer cells.

Tmunity Therapeutics overview

Tmunity Therapeutics (Tmunity) is a biotherapeutics company that discover and develops T cell immunotherapies to treat cancer. The company’s pipeline products include TmPSMA 01 CAR-T, a prostate specific membrane antigen against prostate cancer, TnMUC-1 and TmTN-MUC CAR-T, for the treatment of non-small cell lung; pancreatic; and triple negative breast and ovarian cancer; TmGPC2 01 CAR-T, a glypican 2 targeting neuroblastoma, small cell lung; TMFR 01; a folate receptor for ovarian cancer. It is also investigating Tmuity programs to discover and develop drugs targeting multiple solid tumors such as lung cancer, breast cancer, head and neck cancer. Tmunity utilizies its proprietary T cell therapy platform to produce engineered T cells for suppress immunity including T cell receptors, gene transfer, regulatory T cells, allogeneic T cells, bionic T cells and car-t programs. The company works in collaboration with pharmaceutical and biopharmaceutical companies. Tmunity is headquartered in Philadelphia, Pennsylvania, the US.

For a complete picture of Gene Therapy 2 to Target Mesothelin for Oncology’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.